Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges and to generate the epidemiologic basis for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The program will measure a panel of biomarkers in almost 30,000 individuals in a national study. The project will provide key reference data regarding novel biomarkers for cardiovascular risk stratification and inform U.S. clinical and laboratory guidelines.

Goals

  • Define the reference ranges of hs-cTnT, hs-cTnI, and NT-proBNP in a young, healthy subgroup of adults (N=1,938) and describe age-, gender- and race-specific population values.
  • Characterize the associations of hs-cTnT, hs-cTnI, and NT-proBNP with cardiovascular and total mortality in the U.S. population without clinical cardiovascular disease and to conduct a head-to-head comparison of hs-cTnT to hs-cTnI for mortality risk prediction.

Partners

Abbott
AstraZeneca Pharmaceuticals LP
Dairy Research Institute
Janssen L.P.
Johns Hopkins University
National Heart Lung, and Blood Institute
National Institute of Diabetes and Digestive and Kidney Diseases
Ortho Clinical Diagnostics
Roche
Siemens Healthcare Diagnostics Inc.
University of Maryland
University of Vermont
U.S. Food and Drug Administration

Contact

Tania Kamphaus, Scientific Program Manager, Metabolic Disorders, TKamphaus@fnih.org

Lilit Vardanian, Scientific Project Manager, Metabolic Disorders, lvardanian@fnih.org